Pricing Log in Create free account

Design Therapeutics, Inc. (DSGN) vs Immix Biopharma, Inc. (IMMX)

Design Therapeutics, Inc. and Immix Biopharma, Inc. are both Biotechnology companies. Design Therapeutics, Inc. and Immix Biopharma, Inc. are of similar size ($605.2M and $596.9M). Across the 8 metrics below, Immix Biopharma, Inc. leads on 7 and Design Therapeutics, Inc. on 1.

Valuation

Metric DSGN IMMX Biotechnology median
P/E n/m n/m 10.60
P/S 2,842.20 n/m 9.40
P/B 3.18 2.23 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 1,919.15 n/m 9.02
Earnings yield (11.79%) (10.97%) (32.88%)
Free cash flow yield (9.24%) (7.64%) (23.13%)

Profitability

Metric DSGN IMMX Biotechnology median
Gross margin 0.00% — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (36.87%) (34.18%) (51.96%)
Return on assets (34.57%) (31.34%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DSGN IMMX Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (38.64%) (17.11%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DSGN IMMX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.78 25.13 4.97
Net debt to EBITDA 2.68 3.39 1.01

Dividend

Metric DSGN IMMX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DSGN IMMX Biotechnology median
Market cap 605.16m 596.90m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack